Publicacions en què col·labora amb EDUARDO DÍAZ-RUBIO GARCÍA (38)

2019

  1. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

    Critical Reviews in Oncology/Hematology, Vol. 134, pp. 39-45

2017

  1. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging

    BMC Cancer, Vol. 17, Núm. 1

2015

  1. BRCA1 Alternative splicing landscape in breast tissue samples

    BMC Cancer, Vol. 15, Núm. 1

  2. Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease

    Translational Research, Vol. 166, Núm. 6, pp. 783-787

2014

  1. Assignment of tumor subtype by genomic testing and pathologic-based approximations: Implications on patient's management and therapy selection

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 386-394

  2. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data

    The Lancet Oncology, Vol. 15, Núm. 4, pp. 406-414

  3. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer

    Journal of Cancer Research and Therapeutics, Vol. 10, Núm. 4, pp. 967-972

2013

  1. Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer

    Oncologist, Vol. 18, Núm. 8, pp. 917-923

  2. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients

    Annals of Oncology, Vol. 24, Núm. 3, pp. 655-661

  3. Nuevas estrategias de mejora en la accesibilidad a las pruebas de laboratorio de los pacientes en oncología

    Revista de calidad asistencial, Vol. 28, Núm. 4, pp. 217-223

2012

  1. Glutathione S-transferase P1 c.313a > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients

    Annals of Oncology, Vol. 23, Núm. 7, pp. 1750-1756

2011

  1. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families

    Breast Cancer Research and Treatment, Vol. 129, Núm. 3, pp. 939-946

  2. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome

    Clinical Cancer Research, Vol. 17, Núm. 7, pp. 2006-2013

  3. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

    Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136

  4. Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?

    Clinical and Translational Oncology, Vol. 13, Núm. 7, pp. 451-459

  5. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review

    Clinical and Translational Oncology, Vol. 13, Núm. 2, pp. 121-132

2009

  1. Agentes multidiana anti-tirosín-quinasa

    Tiempos médicos: revista de educación médica continuada, Núm. 657, pp. 40-46

  2. Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 737-747

  3. Circulating tumor cells in metastatic breast cancer: Timing of blood extraction for analysis

    Anticancer Research, Vol. 29, Núm. 10, pp. 4185-4187

  4. Circulating tumor cells in solid tumor in metastatic and localized stages

    Anticancer Research, Vol. 29, Núm. 11, pp. 4839-4843